View Exam | PowerPak

1. Which of the following is an element of cell cycle dysregulation that make CDK4/6 an attractive target for therapeutic intervention in patients with HR+ breast cancer?

A. CDK4/6 is a key regulator of mitosis in the cell cycle. B. CDK4/6 is a promiscuous kinase that activates the cell cycle and multiple pro-survival pathways. C. Activating Rb mutations sensitize breast cancer cells to CDK4/6 inhibitors. D. CDK4/6 is a merging point for multiple mitogenic pathways.

2. BA is a 74-year-old woman with HR+, HER2-negative metastatic breast cancer that recurs several years after completing of 5 years of tamoxifen therapy. Her liver function tests are elevated (aspartate transaminase and alanine transaminase [AST/ALT] are 6 times the upper limit of normal; normal serum bilirubin). Her oncologist wants to administer ribociclib plus letrozole. What, if any, recommendations would you make?

A. Switch to abemaciclib B. No changes to dosing are necessary C. Reduce the starting dose of ribociclib D. Do not use CDK4/6 inhibitors in BA.

3. MG is an 81-year-old woman with HR+, HER2-negative metastatic breast cancer that has recurred following aromatase inhibitor therapy. She has a history of alcohol abuse, which has left her with moderately impaired liver function. She is currently receiving the selective serotonin reuptake inhibitor citalopram. Her oncologist is considering a CDK4/6 inhibitor plus fulvestrant but does not know which to choose. Which CDK4/6 agent(s) would you recommend for MG?

A. Abemaciclib, since it is not associated with QT prolongation B. Palbociclib, since liver toxicity appears to be the least of the CDK4/6 inhibitors C. Ribociclib, since it is unlikely to produce gastrointestinal side effects D. MG can use any of the CDK4/6 inhibitors, since she does not have contraindications to any of them.

4. Approximately, what fraction of the women in the MONARCH-2 trial (abemaciclib vs placebo, plus fulvestrant, in women with HR+, HER2-negative breast cancer progressing during or after adjuvant endocrine therapy) had a measurable response to abemaciclib?

A. 70% B. 50% C. 35% D. 20%

5. How often should patients receiving ribociclib have an electrocardiogram?

A. Baseline, Day 1 of cycles 1–6 B. Baseline, Day 1 of cycles 1 and 2 C. Baseline, Day 1 and Day 14 of cycles 1 and 2 D. Baseline, Day 14 of cycle 1, and Day 1 of cycle 2

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an element of cell cycle dysregulation that make CDK4/6 an attractive target for therapeutic intervention in patients with HR+ breast cancer?

4. Approximately, what fraction of the women in the MONARCH-2 trial (abemaciclib vs placebo, plus fulvestrant, in women with HR+, HER2-negative breast cancer progressing during or after adjuvant endocrine therapy) had a measurable response to abemaciclib?

5. How often should patients receiving ribociclib have an electrocardiogram?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an element of cell cycle dysregulation that make CDK4/6 an attractive target for therapeutic intervention in patients with HR+ breast cancer?

4. Approximately, what fraction of the women in the MONARCH-2 trial (abemaciclib vs placebo, plus fulvestrant, in women with HR+, HER2-negative breast cancer progressing during or after adjuvant endocrine therapy) had a measurable response to abemaciclib?

5. How often should patients receiving ribociclib have an electrocardiogram?

« Return to Activity

Customers who Purchased
this Activity also Purchased